ResearcherTokyo Medical UniversityNo recent work listed

Keisuke Miyazawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8435-1304; OpenAlex author ID A5047620760. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells. Last author DOI 10.3892/or.2021.8251 ↗
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. Last author DOI 10.3892/ijo.2015.3237 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sumire Suzuki · 1 shared paper, 2022 · strength 0.16
- Paper Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer… DOI 10.3892/or.2021.8251 ↗
Shuntaro Mukai · 1 shared paper, 2016 · strength 0.05
- Paper Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell li… DOI 10.3892/ijo.2015.3237 ↗
Xiaofang Che · 1 shared paper, 2016 · strength 0.05
- Paper Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell li… DOI 10.3892/ijo.2015.3237 ↗
Takao Itoi · 1 shared paper, 2016 · strength 0.05
- Paper Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell li… DOI 10.3892/ijo.2015.3237 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.